Sökning: "klinisk farmakologi Uppsala"

Visar resultat 1 - 5 av 36 avhandlingar innehållade orden klinisk farmakologi Uppsala.

1. 1. Preclinical Development of New Alkylating Oligopeptides for Cancer Therapy

   Författare :Joachim Gullbo; Rolf Larsson; Peter Nygren; Staffan Eriksson; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacology; pharmacology; oncology; chemistry; Melphalan derivatives; Farmakologi; Pharmacological research; Farmakologisk forskning;

   Sammanfattning : Oligopeptides can be used to carry cytotoxic agents in cancer chemotherapy, using tumour-associated proteins as the molecular target for selectivity. During the seventies and eighties Peptichemio, a cocktail of six alkylating oligopeptides carrying m-L-sarcolysin, was investigated in a wide variety of human malignancies. LÄS MER

3. 2. On the Prediction of Warfarin Dose

   Författare :Niclas Eriksson; Mia Wadelius; Lars Wallentin; Lars Berglund; Patrik Magnusson; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Warfarin; pharmacogenetics; prediction models; Dosing algorithm; GWAS; VKORC1; CYP2C9; Clinical Pharmacology; Klinisk farmakologi;

   Sammanfattning : Warfarin is one of the most widely used anticoagulants in the world. Treatment is complicated by a large inter-individual variation in the dose needed to reach adequate levels of anticoagulation i.e. INR 2. LÄS MER

4. 3. Integrating Efficacy and Toxicity in Preclinical Anticancer Drug Development : Methods and Applications

   Författare :Caroline Haglund; Elin Lindhagen; Rolf Larsson; Anna Åleskog; Sigurd Vitols; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Anticancer drugs; In vitro assays; Toxicity testing; Haematological toxicity; Primary tumour cells; Species difference; Clinical pharmacology; Klinisk farmakologi; Clinical Pharmacology; Klinisk farmakologi;

   Sammanfattning : Preclinical testing is an important part of cancer drug development. The aim of this thesis was to establish and evaluate preclinical in vitro methods useful in the development of new anticancer drugs. In paper I, the development of non-clonogenic assays (FMCA-GM) using CD34+ stem cells for assessment of haematological toxicity was described. LÄS MER

5. 4. Development and Evaluation of Nonparametric Mixed Effects Models

   Författare :Paul Baverel; Mats Karlsson; Radojka Savic; Nils Hoem; Uppsala universitet; []
   Nyckelord :NATURVETENSKAP; NATURAL SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; nonparametric; model; pharmacometrics; pharmacokinetics; pharmacodynamic; imprecision; covariate analysis; parameter distribution; Statistics; computer and systems science; Statistik; data- och systemvetenskap; Pharmaceutical pharmacology; Farmaceutisk farmakologi; Biopharmaceutics; Biofarmaci; Clinical Pharmacology; Klinisk farmakologi; Computer Systems; Datorteknik; Farmakologi; Pharmacology; Statistics; Statistik;

   Sammanfattning : A nonparametric population approach is now accessible to a more comprehensive network of modelers given its recent implementation into the popular NONMEM application, previously limited in scope by standard parametric approaches for the analysis of pharmacokinetic and pharmacodynamic data. The aim of this thesis was to assess the relative merits and downsides of nonparametric models in a nonlinear mixed effects framework in comparison with a set of parametric models developed in NONMEM based on real datasets and when applied to simple experimental settings, and to develop new diagnostic tools adapted to nonparametric models. LÄS MER

7. 5. Clinical Pharmacogenetics of Olanzapine : with Focus on FMO Gene Polymorphisms

   Författare :Mao Mao Söderberg; Marja-Liisa Dahl; Maria Gabriella Scordo; Inger Johansson; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; olanzapine; pharmacogenetics; drug metabolism; schizophrenia; therapeutic drug monitoring; FMO1; FMO3; CYP1A2; UGT1A4; Clinical Pharmacology; Klinisk farmakologi;

   Sammanfattning : Pharmacogenetics is the study of variability in drug response attributed to genetic variation. Olanzapine (OLA) is a widely used antipsychotic drug for schizophrenia treatment. The pharmacokinetics of OLA display large inter-individual variation leading to multiple-fold differences in drug exposure between patients at a given dose. LÄS MER